Yukon-Nevada Gold,YNG,YNGFF, Profile, Summary
Yukon-Nevada Gold| YNG |YNGFF | Profile | Summary
Yukon-Nevada Gold Corp is listed on the Toronto Stock Exchange (YNG.TO)
and trades on the OTC/Pinksheets under the symbol YNGFF.
Jerritt Canyon, the Company's flagship project, is located in northern Nevada. The Company is currently focused on modernizing the milling facility and emission control systems. The Company is striving to reach a point of renewed profitability accompanied by a significantly reduced environmental impact. Ongoing permitting at Starvation Canyon, Nevada will allow the Company, in the future, to realize an increase in the production of gold ounces at Jerritt Canyon.
The Company is focused on bringing its wholly owned Ketza River property back into production from the Manto Gold Zones and permitting is underway. The Ketza River Property includes the Ketza River mine, which, from 1987 to 1990, produced 98,000 oz of gold and by-product silver from 340,000 tons of ore.
1. Jerritt Canyon - historical production of approximately 8 million oz gold since 1981
+ 100% owned.
+ Permitted and Producing.
+ Current Reserve & Resource includes: 374,800 oz Proven, 686,000 oz Probable, 1.03M oz Measured & 1.29M oz Indicated.
+ Mill engineered capacity of 6,000 tpd of which 5,280 tpd is currently permitted.
2. Ketza River - historical production of 98,000 oz of gold and by-product silver between 1988 - 1990
+ 100% owned.
+ Current Resource includes: 29,000 oz Measured and 388,700 oz Indicated.
+ Site infrastructure well developed.
+ Permitting in progress for mine/mill re-start.
Deutsche Bank invested $40M in equity and $140M gold forward sale.
Planned mine includes 9 open pits and
2 underground declines
+ 83% of the oz to be mined will come from the open pits.
+ Estimated mining rate of 50,000 tpd for the first 2 years and 20,000 tpd in the 3rd year from the open pits.
+ An additional 500 tpd will come from underground mining.
A total of 41% of the measured and indicated recoverable resource ounces are hosted in oxide ores which have a gold recovery of 90%; whereas the other 59% of the measured and indicated recoverable, resource ounces are hosted in sulfide or mixed sulfide+oxide ores that generally have Au recoveries of 70%.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
HEB, Hemispherx Biopharma, Profile, Summary
Editor's Note:
Our members first learned about HEB on Aug 24th and HEB was Featured on our websites including this website on Aug 27th,
Hemispherx Biopharma | HEB | Profile | Summary
Hemispherx Biopharma (HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®.
Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in New Brunswick, New Jersey.
ALFERON
Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.
Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.
ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.
Clinically Effective:
-
All warts disappeared in 54% of patients.3
-
No recurrence in 76% of complete responders at follow-up.3
-
Completely cleared 73% of all treated warts.3,4
-
No human antibodies to interferon alfa-n3 detected in clinical trails.3,4
-
Provides a spectrum of multiple alpha interferon subtypes.1,
What's in the Pipeline?
Ampligen® (poly I:poly C12U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching. Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis and influenza.
Watch This!
On July 31, 2012 Hemispherx submitted its complete response to the FDA’s Complete Response Letter in support of Ampligen®’s New Drug Application for Chronic Fatigue Syndrome (“CFS”).
Its too early to tell what the FDA's response would be, however, the response from investors has been very positive. We alerted our members and followers last week and we believe this company should be on your radar!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
If you want to get your company profiled or have any questions, please don't hesitate to contact the Editor [@ ] PennyStockMonster.com
HOKU, Hoku Corporation, Profile, Summary
Hoku Corporation | HOKU | Profile | Summary
Hoku Corporation (HOKU) is a solar products and services company operating two businesses: Hoku Materials and Hoku Solar. Hoku Materials manufactures, markets and sells polysilicon for the solar industry from its plant currently under construction in Pocatello, Idaho. Hoku Solar is a leading provider of commercial solar power, offering turnkey PV systems and project development services.
Hoku Solar
Hoku Solar – HOKU - is a leading provider of investment-grade solar power, offering project development services, turnkey PV system integration and asset management for solar energy facilities.
Hoku Solar focuses primarily on the commercial and industrial solar market segment, providing large-scale rooftop or ground-mounted PV arrays for businesses, institutions and government clients. We have proven experience with specialty and technical solar products, including third party financed purchase power agreements (PPAs), and building integrated PV. Hoku is also increasingly engaged in the multi-megawatt utility scale market, both as a project developer and as an EPC service provider.
Hoku Solar is active in Hawaii, and is expanding its project development business to other U.S. markets.
Hoku Solar Services
Turnkey PV Integration
Hoku Solar is a full-service solar industry EPC contractor, providing its customers with turnkey engineering, procurement, and construction services for investment-grade PV.
Hoku Solar primarily serves commercial and industrial rooftop customers, large real estate portfolio holders and developers, general contractors, and government and institutional clients.
With proven experience in the Hawaii market, Hoku can deliver a full range of commercial systems, ranging from individual rooftop arrays to multi-megawatt ground-mounted systems.
Project Development
With our unique design and development service offering, Hoku Solar is positioned to bring large-scale and portfolio PV projects to life, whether as lead developer, or as a complement to an existing project team.
Hoku Solar has proven experience at every stage of the PV development cycle – from feasibility studies to commissioning and take-out financing – and we tailor our services to the individual needs of the project. So, whether Hoku is leading the development itself, or contributing to a broader effort, we are focused on scaling up solar in the U.S.
Contact us today and let us put our experience to work for you.
Asset Management
Underperforming solar arrays are underperforming investments. Hoku Solar has the engineering, technical and operational experience to help ensure your target returns are achieved.
We offer customized operations and maintenance programs for a wide variety of commercial systems, each designed to enhance overall system performance and reliability. From system assessment to preventative and corrective maintenance and monitoring, let Hoku Solar’s asset management team help guarantee your PV system’s long-term performance.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Hemispherx Biopharma, HEB, Profile, Summary
Editor's Note: 09/05/2012
Our members first learned about HEB on Aug 24th and HEB was Featured on our websites including this website on Aug 27th,
Hemispherx Biopharma | HEB | Profile | Summary
Hemispherx Biopharma (HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®.
Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in New Brunswick, New Jersey.
ALFERON
Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.
Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.
ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.
Clinically Effective:
-
All warts disappeared in 54% of patients.3
-
No recurrence in 76% of complete responders at follow-up.3
-
Completely cleared 73% of all treated warts.3,4
-
No human antibodies to interferon alfa-n3 detected in clinical trails.3,4
-
Provides a spectrum of multiple alpha interferon subtypes.1,
What's in the Pipeline?
Ampligen® (poly I:poly C12U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching. Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis and influenza.
Watch This!
On July 31, 2012 Hemispherx submitted its complete response to the FDA’s Complete Response Letter in support of Ampligen®’s New Drug Application for Chronic Fatigue Syndrome (“CFS”).
Its too early to tell what the FDA's response would be, however, the response from investors has been very positive. We alerted our members and followers last week and we believe this company should be on your radar!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Penny Stock Monster
Feed Entries
